NewBiotics' strategy is to transform drug resistance into therapeutic advantage.
NewBiotics transforms drug resistances into therapeutic advantages. It focuses on the discovery and development of drug molecules that leverage the cycle of drug resistance in both cancer and infectious diseases.
NewBiotics is a U.S.-based company that was founded in 1997 and the company was acquired by Celmed Biosciences on June 7, 2004.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 27, 2004 | Series E | $4.57M | 1 | — | — | Detail |
Jul 25, 2001 | Series C | $11M | 3 | — | — | Detail |
Apr 4, 2000 | Series Unknown | $6.30M | 1 | Inglewood Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Inglewood Ventures | — | Series E |
Cheng Xin Technology Development Corp | — | Series C |
FAT Capital | — | Series C |